Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omega-3 phospholipid - Acasti Pharma

Next Previous
X
Search
Drug Profile

Omega-3 phospholipid - Acasti Pharma

Alternative Names: CaPre; Long-chain-omega-3-phospholipid; NKPL-66

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acasti Pharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Phospholipids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetes mellitus; Hypertriglyceridaemia

Most Recent Events

  • 31 Aug 2020 Acasti Pharma decides to not submit NDA for Hypertriglyceridaemia (PO) to the US FDA (due to failure in meeting primary endpoint in TRILOGY 2 trial)
  • 31 Aug 2020 Top-line efficacy and adverse events data from the phase III TRILOGY 2 study in Hypertriglyceridaemia released by Acasti Pharma
  • 30 Apr 2020 Acasti Pharma anticipates a formal response on briefing package from the US FDA in June 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top